Generation of stem cell-derived β-cells from patients with type 1 diabetes

We recently reported the scalable in vitro production of functional stem cell-derived beta-cells (SC-beta cells). Here we extend this approach to generate the first SC-beta cells from type 1 diabetic patients (T1D). beta-cells are destroyed during T1D disease progression, making it difficult to extensively study them in the past. These T1D SC-beta cells express beta-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice and respond to anti-diabetic drugs. Furthermore, we use an in vitro disease model to demonstrate the cells respond to different forms of b-cell stress. Using these assays, we find no major differences in T1D SC-beta cells compared with SC-beta cells derived from non-diabetic patients. These results show that T1D SC-beta cells could potentially be used for the treatment of diabetes, drug screening and the study of beta-cell biology.